Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
23.2M
-
Shares change
-
-619K
-
Total reported value, excl. options
-
$142M
-
Value change
-
-$8.84M
-
Put/Call ratio
-
1.48
-
Number of buys
-
36
-
Number of sells
-
-37
-
Price
-
$6.13
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q2 2017
97 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2017.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.2M shares
of 131M outstanding shares and own 17.73% of the company stock.
Largest 10 shareholders include FMR LLC (5.87M shares), NEA Management Company, LLC (4.81M shares), ORBIMED ADVISORS LLC (1.8M shares), FRANKLIN RESOURCES INC (1.25M shares), Polar Capital LLP (1.18M shares), Vivo Capital, LLC (1.01M shares), GOLDMAN SACHS GROUP INC (876K shares), Alyeska Investment Group, L.P. (669K shares), MORGAN STANLEY (563K shares), and Balyasny Asset Management LLC (500K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.